|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C. Chen, M.D., to Vice President of Clinical Development
9/6/2012 10:18:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc. today announced the appointment of Hubert C. Chen, M.D., to vice president of clinical development, endocrine and metabolic disease. This strategic appointment comes as Aileron expands into endocrine and metabolic diseases and prepares to initiate clinical development in early 2013 of its first Stapled Peptide drug candidate, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan disorders including adult growth hormone (GH) deficiency and HIV lipodystrophy, as well as broader patient populations such as GH-deficient abdominal obesity.
|
|
|
|
|
|
|
|
|
|
|